Health Care [ 6/12 ] | Biotechnology [ 45/74 ]
NASDAQ | Common Stock
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer.
Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease.
The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive.
In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications.
Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 25, 24 | -1.15 Decreased by -25.00% | -0.97 Decreased by -18.56% |
| Apr 25, 24 | -0.91 Decreased by -1.11% | -0.93 Increased by +2.15% |
| Feb 22, 24 | -0.96 Decreased by -50.00% | -0.85 Decreased by -12.94% |
| Nov 3, 23 | -0.73 Increased by +6.41% | -0.95 Increased by +23.16% |
| Aug 3, 23 | -0.92 Decreased by -235.29% | -0.87 Decreased by -5.75% |
| Apr 25, 23 | -0.90 Decreased by -5.88% | -0.81 Decreased by -11.11% |
| Feb 23, 23 | -0.64 Decreased by -10.34% | -0.87 Increased by +26.44% |
| Nov 2, 22 | -0.78 Decreased by -13.04% | -0.83 Increased by +6.02% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by -100.00% | -57.59 M Decreased by -47.60% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -45.29 M Decreased by -25.35% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | -60.24 M Decreased by -1.08 K% | -40.73 M Decreased by -67.10% | Increased by +67.63% Increased by +117.02% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -36.21 M Decreased by -20.62% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 60.24 M Increased by 0.00% | -39.01 M Decreased by -245.35% | Decreased by -64.77% Decreased by -245.35% |
| Mar 31, 23 | 521.00 K Decreased by -78.13% | -36.13 M Decreased by -15.46% | Decreased by -6.94 K% Decreased by -427.89% |
| Dec 31, 22 | 6.13 M Decreased by -35.80% | -24.38 M Decreased by -13.90% | Decreased by -397.34% Decreased by -77.41% |
| Sep 30, 22 | 2.06 M Decreased by -34.22% | -30.02 M Decreased by -19.89% | Decreased by -1.46 K% Decreased by -82.25% |